Site Logo
PR001 Administered to International Type 2 Gaucher Disease Patient Via Compassionate Use Pathway
2020-01-10 11:01:04

Prevail Therapeutics has granted a compassionate use request for the administration of PR001 to a single patient with Type 2 Gaucher disease via a compassionate use pathway, following approval by an international regulatory authority, and the patient was recently dosed.

For their full press release click here